The above results indicated that SPL95 ameliorated the fat synthesis-related genes in hyperlipemia rats by regulating the SREBP-1c and HMG-CoA reductase signaling pathway, providing compelling evidence for the potential application of SPL95 on hyperlipidemia. This evidence concerns the gene SREBF1 and hyperlipidemia.